88 related articles for article (PubMed ID: 22132360)
1. Hair loss associated with escitalopram but not with venlafaxine: a case report.
Pitchot W
Prim Care Companion CNS Disord; 2011; 13(4):. PubMed ID: 22132360
[No Abstract] [Full Text] [Related]
2. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder.
Fernandez JL; Montgomery S; Francois C
Pharmacoeconomics; 2005; 23(2):155-67. PubMed ID: 15748090
[TBL] [Abstract][Full Text] [Related]
3. Escitalopram and venlafaxine for the prophylaxis of migraine headache without mood disorders.
Tarlaci S
Clin Neuropharmacol; 2009; 32(5):254-8. PubMed ID: 19667978
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder.
Xie F; Despiegel N; Danchenko N; Hansen K
Int J Psychiatry Clin Pract; 2009; 13(1):59-69. PubMed ID: 24946123
[TBL] [Abstract][Full Text] [Related]
5. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
Bose A; Korotzer A; Gommoll C; Li D
Depress Anxiety; 2008; 25(10):854-61. PubMed ID: 18050245
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder.
Nordström G; Danchenko N; Despiegel N; Marteau F
Value Health; 2012; 15(2):231-9. PubMed ID: 22433753
[TBL] [Abstract][Full Text] [Related]
7. A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway.
François C; Toumi M; Aakhus AM; Hansen K
Eur J Health Econ; 2003; 4(1):12-9. PubMed ID: 15609164
[TBL] [Abstract][Full Text] [Related]
8. Effects of venlafaxine and escitalopram treatments on NMDA receptors in the rat depression model.
Yilmaz N; Demirdas A; Yilmaz M; Sutcu R; Kirbas A; Cure MC; Eren I
J Membr Biol; 2011 Aug; 242(3):145-51. PubMed ID: 21755298
[TBL] [Abstract][Full Text] [Related]
9. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK.
Wade AG; Toumi I; Hemels ME
Curr Med Res Opin; 2005 Apr; 21(4):631-42. PubMed ID: 15899113
[TBL] [Abstract][Full Text] [Related]
10. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
Demyttenaere K; Hemels ME; Hudry J; Annemans L
Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
[TBL] [Abstract][Full Text] [Related]
11. Escitalopram: a pharmacoeconomic review of its use in depression.
Croom KF; Plosker GL
Pharmacoeconomics; 2003; 21(16):1185-209. PubMed ID: 14594439
[TBL] [Abstract][Full Text] [Related]
12. Priorities in treating depression only.
Lam RW
Int J Psychiatry Clin Pract; 2004; 8 Suppl 1():25-9. PubMed ID: 24930686
[TBL] [Abstract][Full Text] [Related]
13. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder.
Montgomery SA; Huusom AK; Bothmer J
Neuropsychobiology; 2004; 50(1):57-64. PubMed ID: 15179022
[TBL] [Abstract][Full Text] [Related]
14. Study of antinociceptive activity of SSRI (fluoxetine and escitalopram) and atypical antidepressants (venlafaxine and mirtazepine) and their interaction with morphine and naloxone in mice.
Sikka P; Kaushik S; Kumar G; Kapoor S; Bindra VK; Saxena KK
J Pharm Bioallied Sci; 2011 Jul; 3(3):412-6. PubMed ID: 21966163
[TBL] [Abstract][Full Text] [Related]
15. EEG Abnormalities Are Associated With Poorer Depressive Symptom Outcomes With Escitalopram and Venlafaxine-XR, but Not Sertraline: Results From the Multicenter Randomized iSPOT-D Study.
Arns M; Gordon E; Boutros NN
Clin EEG Neurosci; 2017 Jan; 48(1):33-40. PubMed ID: 26674366
[TBL] [Abstract][Full Text] [Related]
16. The activity of brain and liver cytochrome P450 2D (CYP2D) is differently affected by antidepressants in the chronic mild stress (CMS) model of depression in the rat.
Haduch A; Rysz M; Papp M; Daniel WA
Biochem Pharmacol; 2018 Oct; 156():398-405. PubMed ID: 30195732
[TBL] [Abstract][Full Text] [Related]
17. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care.
Sørensen J; Stage KB; Damsbo N; Le Lay A; Hemels ME
Nord J Psychiatry; 2007; 61(2):100-8. PubMed ID: 17454724
[TBL] [Abstract][Full Text] [Related]
18. Higher baseline serum adiponectin predicts better treatment remission in patients with generalized anxiety disorder treated with escitalopram.
Shen Z; Wang F; Cui L; Ren L; Hong X; Yuan Y; Shen X
Ann Palliat Med; 2021 Jul; 10(7):7634-7643. PubMed ID: 34353051
[TBL] [Abstract][Full Text] [Related]
19. Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases.
Wang J; Liu X; Mullins CD
Curr Med Res Opin; 2011 Jul; 27(7):1303-13. PubMed ID: 21561393
[TBL] [Abstract][Full Text] [Related]
20. Using meta-regression in performing indirect-comparisons: comparing escitalopram with venlafaxine XR.
Eckert L; Falissard B
Curr Med Res Opin; 2006 Nov; 22(11):2313-21. PubMed ID: 17076991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
